Institution
St Thomas' Hospital
Healthcare•London, United Kingdom•
About: St Thomas' Hospital is a healthcare organization based out in London, United Kingdom. It is known for research contribution in the topics: Population & Pregnancy. The organization has 12105 authors who have published 15596 publications receiving 624309 citations. The organization is also known as: St Thomas's Hospital & St. Thomas's.
Topics: Population, Pregnancy, Antiphospholipid syndrome, Medicine, Cancer
Papers published on a yearly basis
Papers
More filters
••
Carlos III Health Institute1, University College London2, Georgia Regents University3, Southern General Hospital4, King's College London5, Osaka University6, Fukuoka University7, University of Naples Federico II8, Tel Aviv University9, University of Pisa10, University of Cambridge11, Icahn School of Medicine at Mount Sinai12, Royal College of Nursing13, Emory University14, North Tyneside General Hospital15, St Thomas' Hospital16, Baylor College of Medicine17
TL;DR: The results gathered from 545 patients using the definitive version of the NMSQuest are presented highlighting the prevalence of the wide range of NMS flagged in the N MSQuest from consecutive PD patients in an international setting.
Abstract: 2006, there was, no single instrument (questionnaire or scale) for attempting a comprehensive assessment of the wide range of nonmotor symptoms (NMS) of Parkinson's disease (PD). The PD nonmotor group, a multidisciplinary group of experts including patient group representatives developed and validated the NMS screening questionnaire (NMSQuest) comprising 30 items. The NMSQuest is a self completed screening tool designed to draw attention to the presence of NMS. In this paper, we present the results gathered from 545 patients using the definitive version of the NMSQuest highlighting the prevalence of the wide range of NMS flagged in the NMSQuest from consecutive PD patients in an international setting.
477 citations
••
TL;DR: Estimates suggest a heritability of OA of 50% or more, indicating that half the variation in susceptibility to disease in the population is explained by genetic factors.
471 citations
••
TL;DR: SLIT is a safe treatment which significantly reduces symptoms and medication requirements in allergic rhinitis and the size of this benefit compared to that of other available therapies, particularly injection immunotherapy, is not clear.
Abstract: Background
Allergic rhinitis is a common condition which, at its most severe, can significantly impair quality of life despite optimal treatment with antihistamines and topical nasal corticosteroids. Allergen injection immunotherapy significantly reduces symptoms and medication requirements in allergic rhinitis but its use is limited by the possibility of severe systemic reactions. There has therefore been considerable interest in alternative routes for delivery of allergen immunotherapy, particularly the sublingual route.
Objectives
To evaluate the efficacy of sublingual immunotherapy (SLIT), compared with placebo, for reductions in symptoms and medication requirements.
Search strategy
The Cochrane Controlled Trials Register, MEDLINE (1966 to 2002), EMBASE (1974 to 2002) and SciSearch were searched, up to September 2002, using the terms (Rhin* OR hay fever) AND (immunotherap* OR desensiti*ation) AND (sublingual).
Selection criteria
All studies identified by the searches were assessed by the reviewers to identify randomised controlled trials involving participants with symptoms of allergic rhinitis and proven allergen sensitivity, treated with SLIT or corresponding placebo.
Data collection and analysis
Data from identified studies were abstracted onto a standard extraction sheet and subsequently entered into RevMan 4.1. Analysis was performed by the method of Standardised Mean Differences (SMD) using a random-effects model. P values < 0.05 were considered statistically significant. Subgroup analyses were performed according to the type of allergen administered, the age of participants and the duration of treatment.
Main results
Twenty-two trials involving 979 patients were included. There were six trials of SLIT for house dust mite allergy, five for grass pollen, five for Parietaria, two for olive and one each for ragweed, cat, tree and Cupressus. Five studies enrolled exclusively children. Seventeen studies administered the allergen by sublingual drops subsequently swallowed, three by drops subsequently spat out and two by sublingual tablets. Eight studies involved treatment for less than six months, 10 studies for 6 to 12 months and four studies for greater than 12 months. All included studies were double-blind placebo-controlled trials of parallel group design. Concealment of treatment allocation was considered adequate in all studies and the use of identical placebo preparations was almost universal. There was significant heterogeneity, most likely due to widely differing scoring systems between studies, for most comparisons.
Overall there was a significant reduction in both symptoms (SMD -0.42, 95% confidence interval -0.69 to -0.15; p = 0.002) and medication requirements (SMD -0.43 [-0.63, -0.23]; p = 0.00003) following immunotherapy. Subgroup analyses failed to identify a disproportionate benefit of treatment according to the allergen administered. There was no significant reduction in symptoms and medication scores in those studies involving only children but total numbers of participants were too small to make this a reliable conclusion. Increasing duration of treatment does not clearly increase efficacy. The total dose of allergen administered may be important but insufficient data were available to analyse this factor.
Authors' conclusions
SLIT is a safe treatment which significantly reduces symptoms and medication requirements in allergic rhinitis. The size of this benefit compared to that of other available therapies, particularly injection immunotherapy, is not clear, having been assessed directly in very few studies. Further research is required concentrating on optimising allergen dosage and patient selection.
469 citations
••
466 citations
••
University of Calgary1, McGill University Health Centre2, Cardiovascular Institute of the South3, University of British Columbia4, Université du Québec à Trois-Rivières5, Université de Montréal6, Laval University7, McMaster University8, Alberta Health Services9, University of Alberta10, McGill University11, University of Toronto12, Heart and Stroke Foundation of Canada13, Population Health Research Institute14, Montreal General Hospital15, University of Western Ontario16, Montreal Heart Institute17, Winnipeg Regional Health Authority18, Université du Québec à Montréal19, Northern Ontario School of Medicine20, St. Michael's Hospital21, University of Manitoba22, Centre for Addiction and Mental Health23, University of Ottawa24, University Health Network25, Concordia University Wisconsin26, Ottawa Hospital Research Institute27, University of Ontario Institute of Technology28, Hôpital Maisonneuve-Rosemont29, University of Saskatchewan30, Centre Hospitalier Universitaire Sainte-Justine31, Children's Hospital of Eastern Ontario32, St Thomas' Hospital33, Mount Sinai Hospital, Toronto34, Université de Sherbrooke35, Brown University36, Concordia Hospital37, University of Pennsylvania38
TL;DR: All individuals with hypertension should have an assessment of global cardiovascular risk to promote health behaviours that lower blood pressure, and an angiotensin receptor-neprilysin inhibitor combination should be used in place of either an ang Elliotensin-converting enzyme inhibitor or angiotENSin receptor blocker in individuals with heart failure.
465 citations
Authors
Showing all 12132 results
Name | H-index | Papers | Citations |
---|---|---|---|
David J. Hunter | 213 | 1836 | 207050 |
Rory Collins | 162 | 489 | 193407 |
Steven Williams | 144 | 1375 | 86712 |
Geoffrey Burnstock | 141 | 1488 | 99525 |
Nick C. Fox | 139 | 748 | 93036 |
Christopher D.M. Fletcher | 138 | 674 | 82484 |
David A. Jackson | 136 | 1095 | 68352 |
Paul Harrison | 133 | 1400 | 80539 |
Roberto Ferrari | 133 | 1654 | 103824 |
David Taylor | 131 | 2469 | 93220 |
Keith Hawton | 125 | 657 | 55138 |
Nicole Soranzo | 124 | 316 | 74494 |
Roger Williams | 122 | 1455 | 72416 |
John C. Chambers | 122 | 645 | 71028 |
Derek M. Yellon | 122 | 638 | 54319 |